title: [Analysis of the immunological reconstitution, effectiveness and safety of vaccination in children with cancer].
abstract: The aim of this study was an assessment of immunologic reconstitution, efficiency and safety of vaccination performed in course of oncological treatment and after the therapy.
  
  
  METHODS
  129 children aged 1 month-19,5 years with diagnosis of leukemia or lymphoma (74,4%) or a solid tumor (25,6%). Immune status was evaluated 6 months after cessation of treatment in order to plan active immunization. Effectiveness of vaccination against hepatitis B was performed too. PATIENTS who did not complete immunization against hepatitis B at the time of diagnosis continued vaccination according to the scheme 0-1-6 months, the others were given one doubled dose. In 90,7% patients complete immune reconstitution was observed and both mandatory and optional immunization was then resumed. In 5,4% of children vaccination with live vaccines was suspended due to moderate immune deficiencies. In 3,9% of patients severe immune deficiencies were diagnosed and vaccination was abandoned. At diagnosis of cancer double vaccine doses against hepatitis B were given to 94,6% of patients, while 5,4% continued standard vaccination scheme. After anticancer therapy anti-HBs titer >100 IU/ml was observed in 55%, 10-100 IU/ml in 26% and <10 IU/ml in 18,6% of patients. One case of HBV infection was noted. Neither adverse reactions after immunization nor life-threatening infections the patients were vaccinated against was noted. Our Immunization protocol adopted in the study seem to be efficient and safe.
authors.affiliation: Katedra i Klinika Pediatrii, Hematologii i Onkologii Collegium Medicum w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu. akoltan@by.home.pl
authors.forename: Sylwia
authors.initials: S
authors.lastname: Kołtan
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kołtan
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Grześk
authors.forename: Robert
authors.initials: R
authors.lastname: Debski
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006510:Hepatitis B Antibodies / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D011044:Poland; D012449:Safety; D014611:Vaccination
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines